No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S 8.4x · 10Y median 5.4x · 68th percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 27
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T17:52:18.961Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow. Quote observation: 2026-10-06T17:52:18.961Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Quote observation: 2026-10-06T17:52:18.961Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Unrounded diluted TTM EPS / FMP quote price × 100. Quote observation: 2026-10-06T17:52:18.961Z. Latest historical point 2026-05-06.
Four-quarter operating cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-06T17:52:18.961Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter free cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-06T17:52:18.961Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for 908 Devices Inc. (MASS) stock was $12.42 as of Oct 6, 2026, 1:50 PM EDT, down 2.97% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +40.9% · 3-year avg +27.1%/yr · 5-year avg -17.7%/yr
908 Devices Inc. provides purpose-built handheld mass spectrometry and fourier transform infrared (FTIR) devices for use in vital health and safety applications.
Medical - Specialties · Burlington, MA
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
Next Earnings Date
Nov 9, 2026
34 days away
EPS Estimate
-0.16
Revenue Est.
$18.31M
Last Quarter Results
EPS
$-0.06
vs Estimate
$-0.14
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1MASS | $509.56M | $12.42 | -2.97% | +40.89% | -17.66% | N/A | N/A |
| 2CBIO | $506.18M | $13.63 | -2.24% | +18.84% | -24.40% | -22.94% | vs MASS |
| 3ALLO | $503.93M | $1.46 | -2.67% | +12.72% | -42.72% | N/A | vs MASS |
| 4ALT | $515.90M | $2.65 | -0.64% | -31.59% | -25.30% | N/A | vs MASS |
| 5TCMD | $500.14M | $22.17 | -1.32% | +47.55% | -11.73% | +1.68% | vs MASS |
| 6IMMX | $520.89M | $9.57 | -5.48% | +388.03% | N/A | N/A | vs MASS |
forward FY estimate
N/A
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
$16.07M
vs Estimate
$15.37M
Consensus Rating
Based on 4 analysts
Average Price Target
$13.38
+7.7% upside
Low
$12.00
Current
$12.42
High
$14.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.19 | $-0.16 | $-0.12 | 2 |
| Quarter ending Dec 2026 | $-0.13 | $-0.12 | $-0.10 | 2 |
| Quarter ending Mar 2027 | $-0.16 | $-0.15 | $-0.15 | 1 |
| Quarter ending Jun 2027 | $-0.14 | $-0.14 | $-0.13 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-0.98 | $-0.86 | $-0.74 | 3 |
| FY 2027 | $-0.50 | $-0.45 | $-0.41 | 3 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $18.05M | $18.31M | $18.59M | 5 |
| Quarter ending Dec 2026 | $20.89M | $21.29M | $22.00M | 5 |
| Quarter ending Mar 2027 | $16.51M | $16.90M | $17.47M | 4 |
| Quarter ending Jun 2027 | $18.79M | $19.24M | $19.87M | 4 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $69.02M | $69.17M | $69.62M | 5 |
| FY 2027 | $81.75M | $82.54M | $83.66M | 5 |
